Sanofi SA increased its spending on research and development in 2024 as it moved into new technologies and advanced its position in diabetes in order to strengthen its position as a proprietary drug producer. This is ahead of the spin-out of its consumer healthcare business Opella which is expected to take place, at the earliest, in the second quarter. The company’s R&D spend in 2024 was €7.4 billion, up by more than 14% from a year earlier and represented 18% of sales.
